scholarly journals Two-years Biannual Evaluation of Drug-resistant Tuberculosis Patients Completing Their Treatment at Persahabatan General Hospital Jakarta

2020 ◽  
Vol 1 (1) ◽  
pp. 15-32
Author(s):  
Murniati Murniati ◽  
Diah Handayani ◽  
Fathiyah Isbaniah
Keyword(s):  
General Hospital ◽  
Cross Sectional Study ◽  
Treatment Evaluation ◽  
Post Treatment ◽  
Sputum Culture ◽  
Drug Resistant ◽  
Cross Sectional ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
The Mean

Background: Drug-resistant tuberculosis (DR-TB) is a worldwide threat, including in Indonesia, which course of treatments are time consuming and are expensive. Recent findings suggest trends in recurrence of DR-TB, while no data is available to summarize the recurrence of DR-TB in Indonesia. Objective: This study aimed to evaluate DR-TB patients which was biannually performed for two-years (e.g. at the 6th, 12th, 18th, and 24th mos) after treatment completion. Methods: This cross-sectional study involved DR-TB patients completing their treatment at Persahabatan General Hospital Jakarta, Indonesia, between April and December 2017. The post-treatment evaluation during the 6th, 12th, 18th, and 24th mos included clinical, chest x-ray (CXR) and sputum culture examination. Results: Sixty patients were observed in this study, 31 (51.7%) were males and 29 (48.3%) were females. The mean age was 42.3+12.5 yo and the mean body mass index was 21.75+4.34. Fourty nine (81.7%) patients showed extensive lesions per CXR and none of the patient showed Mycobacterium tuberculosis growth per sputum culture. Conclusion: There was no recurrence of DR-TB from patients completing their treatment at Persahabatan General Hospital Jakarta, Indonesia during two-years post-treatment evaluation.

A cross sectional study of drug resistant tuberculosis in previously treated cases

2017 ◽  
Author(s):  
Anshu Gul Punjabi ◽  
Rakesh Waghmare ◽  
Rahul Lokhande ◽  
Tilak Dhamgaye ◽  
Vishwanath Pujari ◽  
...  
Keyword(s):  
Cross Sectional Study ◽  
Drug Resistant ◽  
Sectional Study ◽  
Cross Sectional ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Previously Treated

scholarly journals Routine surveillance for the identification of drug resistant Tuberculosis in Tanzania: A cross-sectional study of stakeholders’ perceptions

PLoS ONE ◽  
2019 ◽  
Vol 14 (2) ◽  
pp. e0212421 ◽  
Author(s):  
Basra Esmail Doulla ◽  
Stephen Bertel Squire ◽  
Eleanor MacPherson ◽  
Esther Stanslaus Ngadaya ◽  
Beatrice Kemilembe Mutayoba ◽  
...  
Keyword(s):  
Cross Sectional Study ◽  
Drug Resistant ◽  
Sectional Study ◽  
Cross Sectional ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Routine Surveillance

scholarly journals Challenges in the diagnosis of drug-resistant tuberculosis by GeneXpert MTB/Rif in Nepal

2018 ◽  
Vol 16 (2) ◽  
pp. 8-15
Author(s):  
S.K. Shrestha ◽  
N.P. Shah ◽  
K.K. Jha ◽  
R.P. Pant ◽  
L.R. Joshi ◽  
...  
Keyword(s):  
Cross Sectional Study ◽  
Nucleic Acid Amplification ◽  
Drug Resistant ◽  
Cross Sectional ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
National Tuberculosis ◽  
Technical Manpower ◽  
The Individual ◽  
Study Participants

Introduction: GeneXpert MTB/Rif assay is an automated, cartridge-based nucleic acid amplification test that can accurately detect both tuberculosis and Rifampicin resistance. Since its introduction, there has been a steady uptake of this technology by the National Tuberculosis Program of Nepal. Nevertheless, a large number of drug-resistant TB cases remains undiagnosed. This study aims to examine the challenges in diagnosis of drug-resistant tuberculosis by the GeneXpert MTB/Rif assay in Nepal and explore the possible solutions. Methods: This was a cross-sectional study consisting of two parts – a quantitative part assessing the individual details and a qualitative part assessing the challenges on the diagnosis of drug-resistant TB by GeneXpert MTB/Rif assay. Data were collected from the GeneXpert operators, clinicians and program managers from 16 centers across the country and analyzed by IBM SPSS for Windows v23 and QDA Miner 4 Lite. Descriptive statistics were used to summarize the sociodemographic and other characteristics of the study participants using mean, standard deviation and proportions as appropriate. Results: A total of 48 technical manpower participated in the study. The mean age was 39.95 years and a majority of them (77.3%) were male. The major challenges identified were inadequate training, frequent power failure, difficulty in maintaining appropriate steady temperature, module failure which is often not replaced in time, issues with calibration and timely availability of cartridges as well as appropriate ways to store the new cartridges and safe disposal of the used cartridges. Conclusion: A number of challenges limit the optimal utilization of GeneXpert MTB/Rif assay warranting action.

scholarly journals Prevalence and risk factors of depression in patients with drug-resistant tuberculosis in Nepal: A cross-sectional study

2020 ◽  
Vol 21 ◽  
pp. 100200
Author(s):  
Sailesh Kumar Shrestha ◽  
Sulochana Joshi ◽  
Ratna Bahadur Bhattarai ◽  
Lok Raj Joshi ◽  
Nilaramba Adhikari ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cross Sectional Study ◽  
Drug Resistant ◽  
Sectional Study ◽  
Cross Sectional ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis

scholarly journals Multi-Drug Resistant Tuberculosis Treatment Outcome and Associated Factors in Addis Ababa, Ethiopia: A Retrospective Cross-Sectional Study

2020 ◽  
Author(s):  
Tadesse Alemu Bekele ◽  
Getasew Amogne Aynalem ◽  
Trhas Tadesse Berhe
Keyword(s):  
Treatment Outcome ◽  
Cross Sectional Study ◽  
Drug Resistant ◽  
Sectional Study ◽  
Cross Sectional ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Multi Drug Resistant Tuberculosis ◽  
Poor Treatment ◽  
Poor Treatment Outcome

Abstract BackgroundDrug-resistant tuberculosis continues to be a public health threat around the globe especially in developing countries. In 2018, the number of new cases of rifampicin-resistant tuberculosis was half a million and about 78% of them had multi-drug resistant tuberculosis. In Ethiopia, the overall proportion of multi-drug resistant tuberculosis was 11.6%. The latest treatment outcome data for people with multi-drug resistant tuberculosis show a global treatment success rate of 56%. Therefore, this study was aimed at assessing multi-drug resistant tuberculosis treatment outcomes and associated factors at St. Peter Specialized Hospital, Ethiopia, 2019. MethodsA retrospective cross-sectional study was done. A total of 384 patient medical charts selected by simple random sampling method were reviewed. The data was collected using a checklist from the patients’ medical charts. The collected data were analyzed with SPSS version 23 computer software package. Summary statistics of a given data for each variable were calculated. A logistic regression model was used to measure the association between the outcome and the predictor variable. Statistical significance was declared at p-value<0.05. Direction and strength of association were expressed using OR and 95% CI. ResultFrom a total of 384 patients, the majority of 245(63.8%) of the study subjects were females. The rate of poor treatment outcome was 173(45.1%). Male patients and patients in the age category of 39-60 years were less likely to have poor treatment outcome compared to female patients and patients in the age category of 18-38 years (AOR = 0.43, 95%CI (0.19, 0.10) and (AOR = 0.28, 95%CI (0.15, 0.52) respectively. Patients with a history of second-line TB drug resistance are more likely to have poor treatment outcomes (AOR = 3.81, 95%CI (1.84, 7.91). Poor treatment outcome was higher among patients with longer treatment duration (AOR = 3.23, 95%CI (1.82, 5.74) compared to patients with short treatment duration. ConclusionThe proportion of poor treatment outcome in patients with multi-drug resistant tuberculosis was high. Therefore, a concerted effort should be done at all levels to improve the treatment outcome of the MDR-TB.

Sign in / Sign up

Export Citation Format

Share Document